Neurological Complications of Chemotherapy

Díaz, María; Schiff, David

doi:10.1007/978-3-030-23417-1_26

Cited by 3 publications

(3 citation statements)

References 114 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sagittal and coronal sway values observed in our sample were worse than those previously associated with falls in elderly populations [66]. Chemotherapy can have neurologic and musculoskeletal impacts affecting mobility including distal sensory loss, ototoxicity, myelopathy, weakness, atrophy, and sarcopenia [67,68]. In addition, glucocorticoids coadministered during chemotherapy and deconditioning from hospitalization for cancer treatment lead to muscle loss that could also underpin decline in mobility [69,70].…”

Section: Comparison With Previous Studiesmentioning

confidence: 53%

Using Wearable Inertial Sensors to Assess Mobility of Patients With Hematologic Cancer and Associations With Chemotherapy-Related Symptoms Before Autologous Hematopoietic Stem Cell Transplant: Cross-sectional Study

Skiba¹,

Harker²,

Guidarelli³

et al. 2022

JMIR Cancer

View full text Add to dashboard Cite

Background Wearable sensors could be a simple way to quantify and characterize mobility in patients with hematologic cancer scheduled to receive autologous hematopoietic stem cell transplant (autoHSCT) and how they may be related to common treatment-related symptoms and side effects of induction chemotherapy. Objective We aimed to conduct a cross-sectional study comparing mobility in patients scheduled to receive autoHSCT with that in healthy, age-matched adult controls and determine the relationships between patient mobility and chemotherapy-related symptoms. Methods Patients scheduled to receive autoHSCT (78/156, 50%) and controls (78/156, 50%) completed the prescribed performance tests using wearable inertial sensors to quantify mobility including turning (turn duration and number of steps), gait (gait speed, stride time, stride time variability, double support time, coronal trunk range of motion, heel strike angle, and distance traveled), and balance (coronal sway, coronal range, coronal velocity, coronal centroidal frequency, sagittal sway, sagittal range, sagittal velocity, and sagittal centroidal frequency). Patients completed the validated patient-reported questionnaires to assess symptoms common to chemotherapy: chemotherapy-induced peripheral neuropathy (Functional Assessment of Cancer Therapy/Gynecologic Oncology Group–Neurotoxicity subscale), nausea and pain (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire), fatigue (Patient-Reported Outcomes Measurement Information System Fatigue Short Form 8a), vertigo (Vertigo Symptom Scale–short form), and depression (Center for Epidemiological Studies–Depression). Paired, 2-sided t tests were used to compare mobility between patients and controls. Stepwise multivariable linear regression models were used to evaluate associations between patient mobility and symptoms. Results Patients aged 60.3 (SD 10.3) years had significantly worse turning (turn duration; P<.001), gait (gait speed, stride time, stride time variability, double support time, heel strike angle, stride length, and distance traveled; all P<.001), and balance (coronal sway; P<.001, range; P<.001, velocity; P=.02, and frequency; P=.02; and sagittal range; P=.008) than controls. In patients, high nausea was associated with worse stride time variability (ß=.001; P=.005) and heel strike angle (ß=−.088; P=.02). Pain was associated with worse gait speed (ß=−.003; P=.003), stride time variability (ß=.012; P=.02), stride length (ß=−.002; P=.004), and distance traveled (ß=−.786; P=.005). Nausea and pain explained 17% to 33% and 14% to 36% of gait variance measured in patients, respectively. Conclusions Patients scheduled to receive autoHSCT demonstrated worse mobility in multiple turning, gait, and balance domains compared with controls, potentially related in part to nausea and pain. Wearable inertial sensors used in the clinic setting could provide granular information about mobility before further treatment, which may in turn benefit from rehabilitation or symptom management. Future longitudinal studies are needed to better understand temporal changes in mobility and symptoms across the treatment trajectory to optimally time, design, and implement strategies, to preserve functioning in patients with hematologic cancer in the long term.

show abstract

Section: Comparison With Previous Studiesmentioning

confidence: 53%

Using Wearable Inertial Sensors to Assess Mobility of Patients With Hematologic Cancer and Associations With Chemotherapy-Related Symptoms Before Autologous Hematopoietic Stem Cell Transplant: Cross-sectional Study

Skiba¹,

Harker²,

Guidarelli³

et al. 2022

JMIR Cancer

View full text Add to dashboard Cite

show abstract

“…Thus, correct identification of responsible anticancer drugs to specific neurological complications affords rapid and proper modification of the offender, circumvention of extra testing, and potential discontinuation of irrelevant mediations. Herein, we summarize the antineoplastic agents associated with neurological complications both in PNS and CNS ( Table 2 ) 45 , 47 , 52 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 . Chemotherapy agents related to peripheral neuropathy cover the majority of conventional anticancer drugs, including alkylating agents (platinum complexes), mitotic inhibitors (taxanes, epothilones, and vinca alkaloids), proteasome inhibitors (bortezomib), and antiangiogenic agents (thalidomides).…”

Section: Complications Induced By Anticancer Chemotherapymentioning

confidence: 99%

Complications and comorbidities associated with antineoplastic chemotherapy: Rethinking drug design and delivery for anticancer therapy

Mao,

Wu,

Huang

et al. 2024

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

“…Furthermore, sensory neuropathy induces complaints of sensory defects in the patient's extremities, de ned as "as if wearing socks and gloves" [5,10,11]. Symptoms usually begin in the ngertips and progress distally to proximally [12][13][14][15]. Because these symptoms cause functional interference with activities of daily life, they negatively affect patients' physical, social, emotional, and functional health and reduce their quality of life.…”

mentioning

confidence: 99%

Determination of the Influence of Peripheral Neuropathy Symptoms on Quality of Life in Breast Cancer Patients Receiving Paclitaxel: Prospective Cross Sectional Study With Four Follow-ups

Kurt

Karslı

Öksüzoğlu

et al. 2021

Preprint

View full text Add to dashboard Cite

Background The objective of this study is to evaluate the impact of peripheral neuropathy on the quality of life of breast cancer patients throughout with monthly follow-up during 4 months of paclitaxel treatment.Material and methods The research was conducted with a prospective cross sectional with four follow-ups descriptive design. The study population consisted of female patients with breast cancer at Ankara Oncology Training and Research Hospital between August 2018 and January 2019. Data were collected the ‘’Patient Information Form’’,‘’EORTC C30 Cancer Quality Of Life Questionnaire’’ and ‘’Chemotherapy-Induced Peripheral Neuropathy Assessment Tool’’. The study was undertaken in accordance with the STROBE checklist for cross-sectional studies. Results Of 79 patients included in the Chemotherapy-Induced Peripheral Neuropathy Assessment Tool except for the general activity subdimension were statistically significant in the ratings of 2nd, compared to 1st; 3rd compared to 1st and 2nd; 4th compared to 1st, 2nd, and 3rd follow-up periods. The overall mean of EORTC C30 Cancer Quality of Life Questionnaire, functional subdimension, symptom severity, and general well-being in the evaluations of 2nd, compared with 1st; 3rd compared with 1st and 2nd; 4th compared with 1st, 2nd, and 3rd follow-up periods it was found that the mean values of symptom that decreased gradually were statistically significant.Conclusion The neuropathy scale was found to be higher in 2nd, 3rd, 4th follow-up periods than in 1st follow-up. Also, EORTC C30 Cancer QLQ subdimensions were high initially but gradually decreased after the fourth cycle. Thus, it was found that the increase in neuropathy symptoms negatively affects the quality of life.

show abstract

Neurological Complications of Chemotherapy

Cited by 3 publications

References 114 publications

Using Wearable Inertial Sensors to Assess Mobility of Patients With Hematologic Cancer and Associations With Chemotherapy-Related Symptoms Before Autologous Hematopoietic Stem Cell Transplant: Cross-sectional Study

Using Wearable Inertial Sensors to Assess Mobility of Patients With Hematologic Cancer and Associations With Chemotherapy-Related Symptoms Before Autologous Hematopoietic Stem Cell Transplant: Cross-sectional Study

Complications and comorbidities associated with antineoplastic chemotherapy: Rethinking drug design and delivery for anticancer therapy

Determination of the Influence of Peripheral Neuropathy Symptoms on Quality of Life in Breast Cancer Patients Receiving Paclitaxel: Prospective Cross Sectional Study With Four Follow-ups

Contact Info

Product

Resources

About